Doms № 1 -2022

PDF

Doms № 1 -2022 (49-53 p)

Efficacy of liraglutide in treatment obesity: in focus of the SCALE study
Cherenko M. S., Mankovskyi B. M.

Download

Abstract

Obesity is a chronic, progressive disease that is associated with increased mortality and risk of development of various diseases, primarily metabolic and cardiovascular, as well as oncological and mental diseases. The prevalence of overweight patients in the population is increasing worldwide as among adults, as well as among children, adolescents and the elderly. Liraglutide, which is actively used to treat type 2 dia- betes in a dose of 1.8 mg/day, showed high efficiency for weight loss at a dose of 3.0 mg per day. Analog glucagon-like peptide liraglutide at a dose of 3.0 mg per day is approved in the European Union, USA, Canada and Ukraine for use to reduce weight as a supplement to diet and exercise in adult patients with obesity (BMI more than 30 kg/m2) or excessive body weight (BMI from 27 to 30 kg/m2) in the presence of at least one accompanying weight-related disease, such as prediabetes or type 2 diabetes type, hypertension, dyslipidemia or obstructive sleep apnea.

Keywords: obesity, excessive body weight, mortality, glucagon-like peptide, liraglutide, weight reduction.

References

 

  1. Booth A., Magnuson A., Fouts J., Foster M.T. Adipose tissue: an endocrine organ playing a role in metabolic regulation // Horm Mol Biol Clin Invest. – 2016. — 18 p. – DOI 10.1515/ hmbci-2015-0073.

  2. Bray G.A., Kim K.K., Wilding JPH & World Obesity Federa- tion. Obesity: a chronic relapsing progressive disease pro- cess. A position statement of the World Obesity Federation // Obesity Reviews. — 2017. — V. 18. — P. 715–723. — https://doi.org/10.1111/obr.12551.

  3. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation // Obes. Rev. — 2017. — V. 18. — P. 715–723. – DOI: 10.1111/ obr.12551

  4. Camilleri M., Acosta A. Combination Therapies for Obesity // Metabolic syndrome and related disorders. — 2018. — V. 16, N.8. — P. 390-394.

  5. Davies M.J., Bergenstal R., Bode B. et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial // JAMA. — 2015. — V. 314(7). — P. 687-699. – doi:10.1001/ jama.2015.9676

  6. Garvey W.T., Birkenfeld A.L., Dicker D. et al. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial // Diabetes Care. — 2020. — V. 43(5). — P. 1085-1093. — https://doi. org/10.2337/dc19-1745

  7. Kelly A.S., Auerbach P., Margarita Barrientos-Perez M. et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity // N Engl J Med. — 2020. — V. 382, N. 22. — 2117-2128. doi: 10.1056/NEJMoa1916038.

  8. Ladenheim E.E. Liraglutide and obesity: a review of the datasofar//DrugDesDevelTher.— 2015.— V.9.— P. 1867-75. doi: 10.2147/DDDT.S58459.

  9. Lin C-H., Shao L., Zhang Y-M. et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity // Expert Opin Pharmacother. — 2020. — 21, N. 3. — P. 275-285. – doi: 10.1080/14656566.2019.1695779.

  10. Mastrandrea L.D., Witten L., Carlsson Petri K.C. et al. Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics // Pediatric Obesity. — 2019. — V. 14. e12495. — 9 p. – https://doi.org/10.1111/ijpo.12495.

  11. Mechanick J.I., Hurley D.L., Garvey W.T. Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement // Endocr Pract. — 2017. — V. 23, N. 3. — P. 372-378.

  12. Mehta A., Marso S.P., Neeland I. J. Liraglutide for weight management: a critical review of the evidence // Obesi- ty science and medicine. — 2016. — 12 p. – https://doi. org/10.1002/osp4.84.

  13. Pastor R., Tur J.A. Liraglutide for the Treatment of Obe- sity: Analyzing Published Reviews // Curr Pharm Des. — 2019. — V. 25, N. 15. — 1783-1790. – doi: 10.2174/1381 612825666190701155737.

  14. Pilitsi E., Farr O.M., Polyzos S.A. et al. Pharmacotherapy of obesity: Available medications and drugs under investigation // Metabolism. — 2019. — V. 92. — P. 170-192. doi: 10.1016/j.metabol.2018.10.010.

  15. Pi-Sunyer X., Astrup A., Ken Fujioka D.M.Sc. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management // N Engl J Med. — 2015. — V. 373. — 11-22. – DOI: 10.1056/NEJMoa1411892

  16. van Can J., Sloth B., Jensen C.B. et al. Effects of the once- daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non- diabetic adults // Int J Obes. – 2014. — V. 38. — P. 784-793. – DOI: 10.1038/ijo.2013.162

  17. A.,TronieriJ.S.,SugimotoD.Liraglutide3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial // Obesity (Silver Spring). — 2020. — V. 28, N. 3. — P. 529-536. – doi: 10.1002/oby.22726.

  18. Wilding J.P.H. Endocrine testing in obesity // Eur J Endo. — 2020. — V. 182. P. C13-C15. – https://doi.org/10.1530/EJE- 20-0099.

  19. Marso S.P., Daniels G.H., Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes // N Engl J Med. — 2016. — V. 375. — P. 311-322. – DOI: 10.1056/NEJMoa1603827

 

 

 

Received: 02.12.2021

Revised: 25.01.2022

Accepted: 15.01.2022